#12 SGLT2i / MRAs / GLP1s, with Katherine Tuttle

#12 SGLT2i / MRAs / GLP1s, with Katherine Tuttle

Prof Melanie Davies - 'Do GLP-1 analogues and SGLT2 inhibitors have a role beyond type 2 diabetes?'Подробнее

Prof Melanie Davies - 'Do GLP-1 analogues and SGLT2 inhibitors have a role beyond type 2 diabetes?'

NUGoKidney Innovation Symposium Webinar Series - Katherine R. Tuttle, MD, FASN, FACP, FNKFПодробнее

NUGoKidney Innovation Symposium Webinar Series - Katherine R. Tuttle, MD, FASN, FACP, FNKF

The Implications of the Latest Data on SGLT2 Inhibitors in Heart Failure: A Unified Approach to T...Подробнее

The Implications of the Latest Data on SGLT2 Inhibitors in Heart Failure: A Unified Approach to T...

The Impact of GLP-1RA and SGLT2i on CKD Progression in Subjects with Diabetes | Peter Rossing, MDПодробнее

The Impact of GLP-1RA and SGLT2i on CKD Progression in Subjects with Diabetes | Peter Rossing, MD

What Are SGLT2 Inhibitors and How Do They Work?Подробнее

What Are SGLT2 Inhibitors and How Do They Work?

Webinar: SGLT2 inhibitors in clinical practiceПодробнее

Webinar: SGLT2 inhibitors in clinical practice

SGLT2i in patients with heart failure. Results of two meta-analysisПодробнее

SGLT2i in patients with heart failure. Results of two meta-analysis

SGLT2Warning_PetersПодробнее

SGLT2Warning_Peters

Benefits of SGLT2 Inhibitors and GLP-1 Receptor AgonistsПодробнее

Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists

SGLT2 Inhibitors and Heart FailureПодробнее

SGLT2 Inhibitors and Heart Failure

Protocols for Safe Use of SGLT2i and GLP1RA in the Hospital SettingПодробнее

Protocols for Safe Use of SGLT2i and GLP1RA in the Hospital Setting

Choosing SGLT2 Inhibitors vs GLP-1 Receptor AgonistsПодробнее

Choosing SGLT2 Inhibitors vs GLP-1 Receptor Agonists

#204 NephMadness 2020: SGLT2 InhibitorsПодробнее

#204 NephMadness 2020: SGLT2 Inhibitors

SGLT2i, GLIP-1A and MRA in Cardiorenal Protection | Monique ChoПодробнее

SGLT2i, GLIP-1A and MRA in Cardiorenal Protection | Monique Cho

#26 Cardiorenal Protection with Newer Antidiabetic AgentsПодробнее

#26 Cardiorenal Protection with Newer Antidiabetic Agents

Early vs. Late Initiation of GLP-1RA and SGLT2 for Cardiometabolic Risk ControlПодробнее

Early vs. Late Initiation of GLP-1RA and SGLT2 for Cardiometabolic Risk Control

Dr Julie Lovshin - SGLT2i Cardiorenal mechanisms in diabetes and beyond - full presentationПодробнее

Dr Julie Lovshin - SGLT2i Cardiorenal mechanisms in diabetes and beyond - full presentation

Актуальное